Yang et al. [103] demonstrated that ginsenoside Rh4 exerts therapeutic effects on NAFLD by regulating bile acid metabolism (in both the liver and intestine), lipid metabolism, and phenotypes associated with hepatic inflammatory factors—all via the farnesoid X receptor (FXR) signaling pathway. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.